Orthocell marks first sales of nerve repair product Remplir in key market of Singapore

Orthocell has started selling its nerve repair product in Singapore, two months after the WA biotech received regulatory approval in the country.

Orthcell shares rose 4 per cent to $1.04 on Thursday after the company reported first sales of Remplir — a collagen wrap used in the repair of peripheral nerve injuries — to its exclusive distribution partner Device Technologies Asia.

The John Van Der Wielen-chaired company said the initial order had been received ahead of a planned Singapore market launch in the first quarter of 2025, demonstrating the quality of the Remplir product.

Singapore represents the first major international market launch outside the existing markets of Australia and New Zealand.

Orthocell said Device Technologies Asia was well placed to gain sales traction due to its established relationships with leading plastic reconstructive and orthopaedic surgeons.

Chief executive Paul Anderson said it was delighted to report first sales to Device Technologies Asia earlier than expected.

“Device Technologies is our chosen distribution partner in Australia, New Zealand and Singapore and have moved quickly to begin selling our leading nerve repair product Remplir in Singapore,” he said

“We expect additional sales, revenue growth and surgeon adoption of Remplir to accelerate in the new year.”

Orthocell had previously said the global market for Remplir was estimated to be over $US3.5 billion ($5.5b).

In July, Orthocell’s other flagship product Striate+ received regulatory approval to commence sales in Canada.

Striate+ is a resorbable collagen membrane used for guided bone and tissue generation in dental procedures.